Abstract

Breast cancer is the most frequently diagnosed malignant tumor in women. Due to the high heterogeneity and multiplicity of histological subtypes within this type of cancer, the expression of breast cancer markers is very diverse. Therefore, a biomarker with high sensitivity and specificity would be extremely important for the correct diagnosis and prognosis assessment in breast cancer patients. Mammaglobin A seems to be such a biomarker. Overexpression of this protein is closely related with carcinogenesis in the mammary gland and is observed in up to 80% of cases of the malignant breast cancers. According to many reports, it is postulated that mammaglobin A may be a promising tool in the diagnostics of cancers but also a prognostic, predictive and therapeutic factor. The information contained in this publication presents the current state of knowledge about the structure of mammaglobin A, its function, role in the tumorigenesis and the use of this protein as a diagnostic marker and therapeutic target in breast cancer.

References

• 1. Al Joudi F.S.: Human mammaglobin in breast cancer: Abrief review of its clinical utility. Indian J. Med. Res., 2014, 139;675–685
  Google Scholar
• 2. Cho N.: Molecular subtypes and imaging phenotypes ofbreast cancer. Ultrasonography, 2016; 35: 281–288
  Google Scholar
• 3. Fuller M.S., Lee C.I., Elmore J.G.: Breast cancer screening: Anevidence-based update. Med. Clin. North Am., 2015; 99: 451–468
  Google Scholar
• 4. Ghersevich S., Ceballos M.P.: Mammaglobin A: Review andclinical utility. Adv. Clin. Chem., 2014; 64: 241–268
  Google Scholar
• 5. Ghossein R.A., Carusone L., Bhattacharya S.: Molecular detectionof micrometastases and circulating tumor cells in melanomaprostatic and breast carcinomas. In vivo, 2000; 14:237–250
  Google Scholar
• 6. Goedegebuure P.S., Watson M.A., Viehl C.T., Fleming T.P:Mammaglobin-based strate-gies for treatment of breast cancer.Curr. Cancer Drug Targets, 2004, 4: 531–542
  Google Scholar
• 7. Hagemann I.S., Pfeifer J.D., Cao D.: Mammaglobin expressionin gynecologic adenocarci-nomas. Hum. Pathol., 2013; 44:628–635
  Google Scholar
• 8. Hamrita B., Ben Nasr H., Hammann P., Kuhn L., Ben AnesA., Dimassi S., Chaieb A., Khairi H., Chahed K.: Towards a betterknowledge of breast cancer physiopathology: the proteomicsapproach. Ann. Biol. Clin., 2012; 70: 553–565
  Google Scholar
• 9. Harbeck N., Gnant M.: Breast cancer. Lancet, 2017; 389: 1134–1150
  Google Scholar
• 10. Hassan E.M., Willmore W.G., McKay B.C., DeRosa M.C.: Invitro selections of mammaglobin A and mammaglobin B aptamersfor the recognition of circulating breast tumor cells. Sci.Rep., 2017; 7: 14487
  Google Scholar
• 11. Hon J.D., Singh B., Sahin A., Du G., Wang J., Wang V.Y., DengF.M., Zhang D.Y., Monaco M.E., Lee P.: Breast cancer molecular subtypes:From TNBC to QNBC. Am. J. Cancer Res., 2016; 6: 1864–1872
  Google Scholar
• 12. Hu Y., Liu P., Wu D., Jiang Y.: Prognostic role of plasma mammaglobinA expression in breast carcinoma patients: A meta-analysis.Oncol. Targets Ther., 2018; 11: 3245–3255
  Google Scholar
• 13. Kamal M., Razaq W., Leslie M., Adhikari S., Tanaka T.: Circulatingtumor cells in breast cancer: A potential liquid biopsy. W:Breast Cancer. From Biology to Medicine, eds.: P.V. Pham. IntechOpen Limited, London 2017
  Google Scholar
• 14. Kim S.W., Goedegebuure P., Gillanders W.E.: Mammaglobin-Ais a target for breast cancer vaccination. Oncoimmunology, 2016;5: e1069940
  Google Scholar
• 15. Liu Y.H., Xu F.P., Liao N., Li L., Zhang G.C., Zhuang H.G., Mei P.,Xu J., Zhu X.L., Luo X.L., Kuang L.J.: Efficacy of intraoperative GeneSearch Breast Lymph Node (BLN) Assay for breast cancer metastasisdetection in sentinel lymph node in Chinese patients. CancerSci., 2010; 101: 1920–1924
  Google Scholar
• 16. Miller E.M., Schwartzberg L.S.: Biosimilars for breast cancer:A review of HER2-targeted antibodies in the United States. Ther.Adv. Med. Oncol., 2019; 11: 1758835919887044
  Google Scholar
• 17. Nicolini A., Carpi A., Ferrari P., Morganti R., Mazzotti V., BarakV., Duffy M.J.: An individual reference limit of the serum CEATPA-CA 15-3 tumor marker panel in the sur-veillance of asymptomaticwomen following surgery for primary breast cancer. CancerManag. Res., 2018; 10: 6879–6886
  Google Scholar
• 18. Picot N., Guerrette R., Beauregard A.P., Jean S., Michaud P.,Harquail J., Benzina S., Robichaud G.A.: Mammaglobin 1 promotesbreast cancer malignancy and confers sensitivi-ty to anticancerdrugs. Mol. Carcinog., 2016; 55:1150–1162
  Google Scholar
• 19. Soini Y., Tuhkanen H., Sironen R., Virtanen I., Kataja V.,Auvinen P., Mannermaa A., Kosma V.M.: Transcription factorszeb1, twist and snai1 in breast carcinoma. BMC Cancer, 2011;11: 73
  Google Scholar
• 20. Soysal S.D., Muenst S., Kan-Mitchell J., Huarte E., Zhang X.,Wilkinson-Ryan I., Fleming T., Tiriveedhi V., Mohanakumar T.,Li L., Herndon J., Oertli D., Goedegebuure S.P., Gillanders W.E.:Identification and translational validation of novel mammaglobin-A CD8 T cell epitopes. Breast Cancer Res. Treat., 2014;147: 527–537
  Google Scholar
• 21. Svoboda M., Navrátil J., Slabý O.: Immunotherapy for theprevention and treatment of breast cancer. Klin. Onkol., 2015;28: 416–425
  Google Scholar
• 22. Wang J., Xu B.: Targeted therapeutic options and futureperspectives for HER2-positive breast cancer. Sig. Transduct.Target Ther., 2019; 4: 34
  Google Scholar
• 23. Zehentner B.K., Carter D.: Mammaglobin: A candidate diagnosticmarker for breast can-cer. Clin. Biochem., 2004; 37: 249–257
  Google Scholar
• 24. Zuo L., Li L., Wang Q., Fleming T.P., You S.: Mammaglobinas a potential molecular target for breast cancer drug delivery.Cancer Cell Int., 2009; 9: 8
  Google Scholar

Full text